O T Okoye1, R Gelbard1, K Inaba2, M Esparza1, H Belzberg1, P Talving1, P G Teixeira1, L S Chan1, D Demetriades1. 1. Division of Trauma Surgery and Surgical Critical Care, LAC + USC Medical Center, 2051 Marengo Street, C5L100, Los Angeles, CA, 90033, USA. 2. Division of Trauma Surgery and Surgical Critical Care, LAC + USC Medical Center, 2051 Marengo Street, C5L100, Los Angeles, CA, 90033, USA. kenji.inaba@med.usc.edu.
Abstract
BACKGROUND: The use of low-molecular-weight heparin (LMWH) for the chemoprophylaxis of venous thromboembolism (VTE) in trauma patients is supported by Level-1 evidence. Because Enoxaparin was the agent used in the majority of studies for establishing the efficacy of LMWH in VTE, it remains unclear if Dalteparin provides an equivalent effect. OBJECTIVE: To compare Dalteparin to Enoxaparin and investigate their equivalence as VTE prophylaxis in trauma. PATIENTS/ SETTING: Trauma patients receiving VTE chemoprophylaxis in the Surgical Intensive Care Unit of a Level-1 Trauma Center from 2009 (Enoxaparin) to 2010 (Dalteparin) were included. MEASUREMENTS: The primary outcome was the incidence of clinically significant VTE. Secondary outcomes included heparin-induced thrombocytopenia (HIT), major bleeding, and drug acquisition cost savings. Equivalence margins were set between -5 and 5 %. MAIN RESULTS: A total of 610 patient records (277 Enoxaparin, 333 Dalteparin) were reviewed. The two study groups did not differ significantly: blunt trauma 67 vs. 62 %, p = 0.27; mean Injury Severity Score (ISS) 17 ± 10 vs. 16 ± 10, p = 0.34; Acute Physiology and Chronic Health Evaluation (APACHE) II score 17 ± 9 vs. 17 ± 10, p = 0.76; time to first dose of LMWH 69 ± 98 vs. 65 ± 67 h, p = 0.57). The rates of deep venous thrombosis (DVT) (3.2 vs. 3.3 %, p = 1.00), pulmonary emboli (PE) (1.8 vs. 1.2 %, p = 0.74), and overall VTE (5.1 vs. 4.5 %, p = 0.85) did not differ. The absolute difference in the incidence of overall VTE was 0.5 % [95 % confidence interval (CI): -2.9, 4.0 %, p = 0.85]. The 95 % CI was within the predefined equivalence margins. There were no significant differences in the frequency of HIT or major bleeding. The total year-on-year cost savings, achieved with 277 patients during the switch to Dalteparin, was estimated to be $107,778. CONCLUSIONS: Dalteparin is equivalent to Enoxaparin in terms of VTE in trauma patients and can be safely used in this population, with no increase in complications and significant cost savings.
BACKGROUND: The use of low-molecular-weight heparin (LMWH) for the chemoprophylaxis of venous thromboembolism (VTE) in traumapatients is supported by Level-1 evidence. Because Enoxaparin was the agent used in the majority of studies for establishing the efficacy of LMWH in VTE, it remains unclear if Dalteparin provides an equivalent effect. OBJECTIVE: To compare Dalteparin to Enoxaparin and investigate their equivalence as VTE prophylaxis in trauma. PATIENTS/ SETTING:Traumapatients receiving VTE chemoprophylaxis in the Surgical Intensive Care Unit of a Level-1 Trauma Center from 2009 (Enoxaparin) to 2010 (Dalteparin) were included. MEASUREMENTS: The primary outcome was the incidence of clinically significant VTE. Secondary outcomes included heparin-induced thrombocytopenia (HIT), major bleeding, and drug acquisition cost savings. Equivalence margins were set between -5 and 5 %. MAIN RESULTS: A total of 610 patient records (277 Enoxaparin, 333 Dalteparin) were reviewed. The two study groups did not differ significantly: blunt trauma 67 vs. 62 %, p = 0.27; mean Injury Severity Score (ISS) 17 ± 10 vs. 16 ± 10, p = 0.34; Acute Physiology and Chronic Health Evaluation (APACHE) II score 17 ± 9 vs. 17 ± 10, p = 0.76; time to first dose of LMWH 69 ± 98 vs. 65 ± 67 h, p = 0.57). The rates of deep venous thrombosis (DVT) (3.2 vs. 3.3 %, p = 1.00), pulmonary emboli (PE) (1.8 vs. 1.2 %, p = 0.74), and overall VTE (5.1 vs. 4.5 %, p = 0.85) did not differ. The absolute difference in the incidence of overall VTE was 0.5 % [95 % confidence interval (CI): -2.9, 4.0 %, p = 0.85]. The 95 % CI was within the predefined equivalence margins. There were no significant differences in the frequency of HIT or major bleeding. The total year-on-year cost savings, achieved with 277 patients during the switch to Dalteparin, was estimated to be $107,778. CONCLUSIONS:Dalteparin is equivalent to Enoxaparin in terms of VTE in traumapatients and can be safely used in this population, with no increase in complications and significant cost savings.
Authors: D Green; M Y Lee; A C Lim; J S Chmiel; M Vetter; T Pang; D Chen; L Fenton; G M Yarkony; P R Meyer Journal: Ann Intern Med Date: 1990-10-15 Impact factor: 25.391
Authors: Elliott R Haut; Kathy Noll; David T Efron; Sean M Berenholz; Adil Haider; Edward E Cornwell; Peter J Pronovost Journal: J Trauma Date: 2007-11
Authors: Faye Y Chiou-Tan; Hector Garza; Kwai-Tung Chan; Kenneth C Parsons; William H Donovan; Claudia S Robertson; Sally Ann Holmes; Daniel E Graves; Diana H Rintala Journal: Am J Phys Med Rehabil Date: 2003-09 Impact factor: 2.159
Authors: Todd A Miano; Adam Cuker; Jason D Christie; Niels Martin; Brian Smith; Amy T Makley; Wensheng Guo; Sean Hennessy Journal: Chest Date: 2017-08-18 Impact factor: 9.410
Authors: Todd A Miano; Grigor Abelian; Mark J Seamon; Kristen Chreiman; Patrick M Reilly; Niels D Martin Journal: J Am Coll Surg Date: 2019-02-15 Impact factor: 6.113
Authors: Heba Wagih Abdelwahab; Shaker Wagih Shaltout; Hazem A Sayed Ahmed; Ahmed Mahmoud Fouad; Eric Merrell; Jeffrey B Riley; Rasha Salama; Ahmed Gharib Abdelrahman; Edward Darling; Ghada Fadel; Mohamed S A Elfar; Khaled Sabry; Jaffer Shah; Hossam Amin; Gary F Nieman; Adel Mishriky; Hani Aiash Journal: Clin Drug Investig Date: 2021-07-30 Impact factor: 2.859